Can monoclonal antibodies be the solution for chronic pain?

You must be logged in to participate.
  • Yes, monoclonal antibodies have shown promising results in the treatment of migraines and chronic headaches
  • Maybe, as monoclonal antibodies remain in the body longer than opioids and NSAIDs, they could provide relief for a prolonged time
  • No, the extended duration in the body poses a challenge and could result in adverse side effects

Tagged: Monoclonal

Viewing 4 reply threads
  • Author
    Posts
    • #37793
      Seema Waghmareswaghmare
      Moderator
      Up
      1
      Down
      ::

      During the COVID-19 pandemic, monoclonal antibodies were utilized to destroy the virus by blocking its ability to bind to protein receptors in the human body. This new approach has inspired scientists to explore the use of monoclonal antibodies in treating chronic pain, as they offer a more sustainable and effective solution compared to traditional pain management strategies such as opioids and NSAIDs.
      While opioids provide temporary pain relief, they often lose their efficacy over time and can lead to harmful side effects such as addiction, tolerance, and even life-threatening respiratory distress. On the other hand, monoclonal antibodies last longer in the body, potentially providing sustained pain relief for several weeks, as opposed to just hours or days with opioids.
      The use of monoclonal antibodies in pain management is promising for individuals with chronic conditions such as osteoarthritis, rheumatoid arthritis, lower back pain, neuropathic pain, or cancer-related pain. These antibodies would be designed to target specific ion channels on nerve cells responsible for receiving signals caused by painful stimuli, effectively shutting off the transmission of chronic pain.
      https://www.nationalgeographic.com/magazine/article/could-this-be-the-solution-to-chronic-pain-opioid-crisis-monoclonal-antibody
      fremanezumab – medtigo
      eptinezumab – medtigo

      • This topic was modified 10 months ago by Seema Waghmareswaghmare.
    • #37896
      Robert SchwartzRobert Schwartz
      Participant
      Up
      1
      Down
      ::

      My concern with pain relief is the masking of the deriving factor of why is their pain. Use of natural occurring forms of our innate abilities is a part of our auto immune defense. Identify the binding molecules that promotes the uses of antibodies and how other replacement therapy may offset the advantage of our adaptive immunity. I prefer diet and exercise that through proper channels make us less dependent on pharmaceutical remedies.

      • #37975
        Pranad KshirsagarPranad Kshirsagar
        Participant
        Up
        1
        Down
        ::

        I believe pharmaceuticals are required in conditions with chronic pain. Monoclonal antibodies can ease the pain if it is developed to target pain signals,

    • #37906
      Shannon ChristianShannon Christian
      Participant
      Up
      0
      Down
      ::

      It would be alot better than most options for pain control. And with migraines, anything new is very appreciated for tx.

    • #37943
      null nullaishatusnasara9
      Participant
      Up
      0
      Down
      ::

      During the COVID-19 pandemic, monoclonal antibodies were utilized to destroy the virus by blocking its ability to bind to protein receptors in the human body. This new approach has inspired scientists to explore the use of monoclonal antibodies in treating chronic pain, as they offer a more sustainable and effective solution compared to traditional pain management strategies such as opioids and NSAIDs.
      While opioids provide temporary pain relief, they often lose their efficacy over time and can lead to harmful side effects such as addiction, tolerance, and even life-threatening respiratory distress. On the other hand, monoclonal antibodies last longer in the body, potentially providing sustained pain relief for several weeks, as opposed to just hours or days with opioids.
      The use of monoclonal antibodies in pain management is promising for individuals with chronic conditions such as osteoarthritis, rheumatoid arthritis, lower back pain, neuropathic pain, or cancer-related pain. These antibodies would be designed to target specific ion channels on nerve cells responsible for receiving signals caused by painful stimuli, effectively shutting off the transmission of chronic pain.
      https://www.nationalgeographic.com/magazine/article/could-this-be-the-solution-to-chronic-pain-opioid-crisis-monoclonal-antibody
      fremanezumab – medtigo
      eptinezumab – medtigo

      • This topic was modified 10 months ago by Seema Waghmareswaghmare.
    • #57930
      Christelle Santellisciencehaircare00
      Participant
      Up
      0
      Down
      ::

      Monoclonal antibodies are primarily used to target specific proteins or cells in the body. While they may not directly target abnormal pain signals, they can indirectly ease chronic pain by targeting the underlying causes, such as inflammation or autoimmune responses, which can contribute to pain. Monoclonal antibodies may be part of a pain management strategy for conditions with an inflammatory component.

Viewing 4 reply threads
  • You must be logged in to reply to this topic.